Linked Life Data

18398740

Source:http://linkedlifedata.com/resource/pubmed/id/18398740

Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:18398740rdf:typepubmed:Citationlld:pubmed
pubmed-article:18398740lifeskim:mentionsumls-concept:C0024299lld:lifeskim
pubmed-article:18398740lifeskim:mentionsumls-concept:C0030705lld:lifeskim
pubmed-article:18398740lifeskim:mentionsumls-concept:C0013216lld:lifeskim
pubmed-article:18398740lifeskim:mentionsumls-concept:C1274040lld:lifeskim
pubmed-article:18398740lifeskim:mentionsumls-concept:C0681842lld:lifeskim
pubmed-article:18398740lifeskim:mentionsumls-concept:C1831743lld:lifeskim
pubmed-article:18398740lifeskim:mentionsumls-concept:C0332293lld:lifeskim
pubmed-article:18398740lifeskim:mentionsumls-concept:C0332283lld:lifeskim
pubmed-article:18398740lifeskim:mentionsumls-concept:C1705294lld:lifeskim
pubmed-article:18398740pubmed:issue4lld:pubmed
pubmed-article:18398740pubmed:dateCreated2008-4-9lld:pubmed
pubmed-article:18398740pubmed:abstractTextWe evaluated the prognostic role of 18FDG-PET performed before ASCT in patients affected by lymphoma who underwent high-dose chemotherapy followed by ASCT as first-line treatment for high-risk disease or as second-line or more for relapsed or refractory disease. We retrospectively analyzed 53 consecutive patients, 14 with Hodgkin Lymphoma (HL) and 39 with non-Hodgkin Lymphoma (NHL), treated between February 1999 and October 2006 at our institution, who had a pre-ASCT FDG-PET (pPET) evaluation. Median age was 45 years (range: 18-69). After a median follow-up of 31 months (range: 8-91), 7 out of 16 pPET+ patients and 10 out of 37 pPET- patients experienced lymphoma relapse. The 5-year OS is 90% and 55% (p = 0.01) in patients with negative and positive pPET, respectively. In conclusion, a positive pPET indicates a poorer outcome after ASCT with respect to a negative pPET; this subset of patients should be considered candidate to more intensive or investigational approaches.lld:pubmed
pubmed-article:18398740pubmed:languageenglld:pubmed
pubmed-article:18398740pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18398740pubmed:citationSubsetIMlld:pubmed
pubmed-article:18398740pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18398740pubmed:statusMEDLINElld:pubmed
pubmed-article:18398740pubmed:monthAprlld:pubmed
pubmed-article:18398740pubmed:issn1029-2403lld:pubmed
pubmed-article:18398740pubmed:authorpubmed-author:Caligaris-Cap...lld:pubmed
pubmed-article:18398740pubmed:authorpubmed-author:CiceriFabioFlld:pubmed
pubmed-article:18398740pubmed:authorpubmed-author:BordignonClau...lld:pubmed
pubmed-article:18398740pubmed:authorpubmed-author:PeccatoriJaco...lld:pubmed
pubmed-article:18398740pubmed:authorpubmed-author:BernardiMassi...lld:pubmed
pubmed-article:18398740pubmed:authorpubmed-author:ServidaPaoloPlld:pubmed
pubmed-article:18398740pubmed:authorpubmed-author:GianolliLuigi...lld:pubmed
pubmed-article:18398740pubmed:authorpubmed-author:FazioFerrucci...lld:pubmed
pubmed-article:18398740pubmed:authorpubmed-author:CrocchioloRob...lld:pubmed
pubmed-article:18398740pubmed:authorpubmed-author:CanevariCarla...lld:pubmed
pubmed-article:18398740pubmed:authorpubmed-author:LandoniClaudi...lld:pubmed
pubmed-article:18398740pubmed:authorpubmed-author:LunghiFrances...lld:pubmed
pubmed-article:18398740pubmed:authorpubmed-author:AssanelliAndr...lld:pubmed
pubmed-article:18398740pubmed:authorpubmed-author:TassaraMichel...lld:pubmed
pubmed-article:18398740pubmed:authorpubmed-author:StanghelliniM...lld:pubmed
pubmed-article:18398740pubmed:authorpubmed-author:ClericiDaniel...lld:pubmed
pubmed-article:18398740pubmed:authorpubmed-author:FerreriAndres...lld:pubmed
pubmed-article:18398740pubmed:issnTypeElectroniclld:pubmed
pubmed-article:18398740pubmed:volume49lld:pubmed
pubmed-article:18398740pubmed:ownerNLMlld:pubmed
pubmed-article:18398740pubmed:authorsCompleteYlld:pubmed
pubmed-article:18398740pubmed:pagination727-33lld:pubmed
pubmed-article:18398740pubmed:meshHeadingpubmed-meshheading:18398740...lld:pubmed
pubmed-article:18398740pubmed:meshHeadingpubmed-meshheading:18398740...lld:pubmed
pubmed-article:18398740pubmed:meshHeadingpubmed-meshheading:18398740...lld:pubmed
pubmed-article:18398740pubmed:meshHeadingpubmed-meshheading:18398740...lld:pubmed
pubmed-article:18398740pubmed:meshHeadingpubmed-meshheading:18398740...lld:pubmed
pubmed-article:18398740pubmed:meshHeadingpubmed-meshheading:18398740...lld:pubmed
pubmed-article:18398740pubmed:meshHeadingpubmed-meshheading:18398740...lld:pubmed
pubmed-article:18398740pubmed:meshHeadingpubmed-meshheading:18398740...lld:pubmed
pubmed-article:18398740pubmed:meshHeadingpubmed-meshheading:18398740...lld:pubmed
pubmed-article:18398740pubmed:meshHeadingpubmed-meshheading:18398740...lld:pubmed
pubmed-article:18398740pubmed:meshHeadingpubmed-meshheading:18398740...lld:pubmed
pubmed-article:18398740pubmed:meshHeadingpubmed-meshheading:18398740...lld:pubmed
pubmed-article:18398740pubmed:meshHeadingpubmed-meshheading:18398740...lld:pubmed
pubmed-article:18398740pubmed:meshHeadingpubmed-meshheading:18398740...lld:pubmed
pubmed-article:18398740pubmed:meshHeadingpubmed-meshheading:18398740...lld:pubmed
pubmed-article:18398740pubmed:meshHeadingpubmed-meshheading:18398740...lld:pubmed
pubmed-article:18398740pubmed:year2008lld:pubmed
pubmed-article:18398740pubmed:articleTitlePre-transplant 18FDG-PET predicts outcome in lymphoma patients treated with high-dose sequential chemotherapy followed by autologous stem cell transplantation.lld:pubmed
pubmed-article:18398740pubmed:affiliationHematology and BMT Unit, Department of Oncology, San Raffaele Scientific Institute, Milano, Italy. crocchiolo.roberto@hsr.itlld:pubmed
pubmed-article:18398740pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:18398740pubmed:publicationTypeEvaluation Studieslld:pubmed